Myriad Genetics Submits First Module of Premarket Approval Application to FDA for myChoice® HRD CDx Test
New Studies Highlight Performance of Vectra Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab
Landmark Study Shows GeneSight Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder
Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
